
    
      This study will be performed as a multi-center study which includes 2 centres. 44 subjects
      with T2DM are to be included according to the defined in- and exclusion criteria.

      Subjects has to be on a stable metformin therapy and will receive in a first step
      empagliflozin for 30 days. Both therapies (metformin and empagliflozin) will be continued for
      another 30 days and subjects will be randomized to receive in addition Linagliptin or Placebo
      for 30 days.

      Subjects will come for two inhouse periods to their corresponding study center and will
      undergo an hyperglycaemic clamp test as well as a Meal test in each of the periods.
    
  